Actinia® hip stems

K232371 · Implantcast GmbH · LZO · Oct 19, 2023 · Orthopedic

Device Facts

Record IDK232371
Device NameActinia® hip stems
ApplicantImplantcast GmbH
Product CodeLZO · Orthopedic
Decision DateOct 19, 2023
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3353
Device ClassClass 2
AttributesTherapeutic

Intended Use

The Actinia® hip stems are intended to be used in total hip arthroplasty for the following indications: - · Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis; - · Rheumatoid arthritis; · Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement that are unmanageable by other techniques; and - Revision of previously failed total hip arthroplasty. The Actinia® hip stems cementless are intended for uncemented, press-fit fixation. The Actinia® hip stems are intended to be used in partial (hemi) hip arthroplasty in conjunction with the ic-Bipolar Head System for the following indications: • Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis - Rheumatoid arthritis - · Correction of functional deformity · Treatment of non-union, femoral neck fracture and trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.

Device Story

Actinia® hip stems are monoblock, tapered, cementless femoral components for total or hemi-hip arthroplasty. Manufactured from titanium alloy with hydroxyapatite (HA) coating; designed for press-fit fixation. Available in collared/collarless variants and standard/lateralized/coxa vara configurations. Used in orthopedic surgery by physicians to replace diseased or fractured femoral heads/necks. Compatible with previously cleared ic-Bipolar Head System and EcoFit® Hip System components. Device provides structural support for hip joint; restores joint function; alleviates pain associated with degenerative disease or trauma. Clinical benefit derived from stable fixation and restoration of hip biomechanics.

Clinical Evidence

Bench testing only. Evaluations included fatigue testing (ISO 7206-4/6), impingement testing (ASTM F2582-14), taper disassembly (ASTM F2009), range of motion (ISO 21535), coating characterization (ASTM F1609, F1926, F2024, ISO 13779), and corrosion/fretting performance. All testing met predetermined acceptance criteria.

Technological Characteristics

Monoblock, tapered (12/14) femoral stems; titanium alloy; hydroxyapatite (HA) coating. Press-fit fixation. Standards: ISO 7206-4/6 (fatigue), ASTM F2582-14 (impingement), ASTM F2009 (taper), ISO 21535 (ROM), ASTM F1609/F1926/F2024/ISO 13779 (coating).

Indications for Use

Indicated for patients requiring total or partial (hemi) hip arthroplasty due to non-inflammatory degenerative joint disease (osteoarthritis, avascular necrosis), rheumatoid arthritis, functional deformity, or proximal femur fractures (non-union, femoral neck, trochanteric) unmanageable by other techniques, and for revision of failed total hip arthroplasty.

Regulatory Classification

Identification

A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement.

Predicate Devices

Reference Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health and Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. October 19, 2023 implantcast, GmbH % Juliane Hoppner Regulatory Affairs Manager Implantcast GmbH Luneburger Schanze 26 Buxtehude, Germany Re: K232371 Trade/Device Name: Actinia® hip stems Regulation Number: 21 CFR 888.3353 Regulation Name: Hip Joint Metal/Ceramic/Polymer Semi-Constrained Cemented Or Nonporous Uncemented Prosthesis Regulatory Class: Class II Product Code: LZO, MEH, KWY Dated: August 8, 2023 Received: August 8, 2023 Dear Juliane Hoppner: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality System (OS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). {2}------------------------------------------------ Sincerely, Image /page/2/Picture/3 description: The image shows the text "Limin Sun -S" in a large, bold font. The text is black and is set against a white background. The letters are evenly spaced and easy to read. There is a light blue watermark in the background. Limin Sun, Ph.D. Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ ## Indications for Use Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below. 510(k) Number (if known) K232371 Device Name Actinia® hip stems Indications for Use (Describe) The Actinia® hip stems are intended to be used in total hip arthroplasty for the following indications: - · Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis; - · Rheumatoid arthritis; · Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement that are unmanageable by other techniques; and - Revision of previously failed total hip arthroplasty. The Actinia® hip stems cementless are intended for uncemented, press-fit fixation. The Actinia® hip stems are intended to be used in partial (hemi) hip arthroplasty in conjunction with the ic-Bipolar Head System for the following indications: • Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis - Rheumatoid arthritis - · Correction of functional deformity · Treatment of non-union, femoral neck fracture and trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques. | Type of Use (Select one or both, as applicable) | | |----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------| | <div> <span> ☒ Prescription Use (Part 21 CFR 801 Subpart D) </span> </div> | <div> <span> □ Over-The-Counter Use (21 CFR 801 Subpart C) </span> </div> | ## CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. ## *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {4}------------------------------------------------ ## 510(K) SUMMARY | Manufacturer: | implantcast GmbH<br>Lueneburger Schanze 26<br>21614 Buxtehude<br>Germany | |----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Contact: | Ms. Juliane Höppner<br>Phone: +49 4161 744-135<br>Fax: +49 4161 744-200<br>j.hoeppner@implantcast.de | | Prepared By: | Ms. Hannah Irwin<br>MCRA, LLC<br>1050 K Street NW, Suite 1000<br>Washington, DC 20001<br>Phone: 202.552.5820<br>hirwin@mcra.com | | Date Prepared: | October 17, 2023 | | Device Trade Name: | Actinia® hip stems | | Device Class and<br>Common Name: | Class II, Uncemented Hip Prothesis | | Classification: | 21 CFR 888.3353: Hip Joint Metal/Ceramic/Polymer Semi-<br>Constrained Cemented or Nonporous Uncemented Prosthesis<br><br>21 CFR 888.3390: Hip joint femoral (hemi-hip)<br>metal/polymer cemented or uncemented prosthesis | | Product Codes: | LZO, MEH, KWY | | Indications for Use: | The Actinia® hip stems are intended to be used in total hip<br>arthroplasty for the following indications:<br>• Non-inflammatory degenerative joint disease including<br>osteoarthritis and avascular necrosis;<br>• Rheumatoid arthritis;<br>• Treatment of non-union, femoral neck fracture, and<br>trochanteric fractures of the proximal femur with head<br>involvement that are unmanageable by other techniques;<br>and<br>• Revision of previously failed total hip arthroplasty. | {5}------------------------------------------------ The Actinia® hip stems cementless are intended for uncemented, press-fit fixation. The Actinia® hip stems are intended to be used in partial (hemi) hip arthroplasty in conjunction with the ic-Bipolar Head System for the following indications: - . Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis - Rheumatoid arthritis - Correction of functional deformity - Treatment of non-union, femoral neck fracture and ● trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques. - The purpose of this Traditional 510(k) is to introduce Device Description: into interstate commerce in the United States the Actinia® hip stems. The Actinia® hip stems are femoral stems for total or hemi hip arthroplasty. The Actinia® hip stems include collared and collarless variants in standard and lateralized offset configurations. both Additionally, the scope includes the coxa vara hip stem variant in a standard offset configuration. The Actinia® hip stems are monoblock, tapered straight stems made from titanium alloy with a coating of hydroxyapatite (HA). They are fixed by press-fitting. The Actinia® hip stems are to be used alongside other previously cleared components to make a complete prosthesis. Specifically, Actinia® hip stems are compatible with legally marketed heads used with the implantcast EcoFit® Hip System (K163577, K180263 and K191569) and the implantcast ic-Bipolar Head System (K191569). - Predicate Devices: · implaFit® hip stems (K210678) Reference Devices: - DePuy Orthopaedics, Inc. Corail AMT Hip Prosthesis . (K203167) - EcoFit® Hip System (K163577, K180263, K191569 and . K203420) Substantial The Actinia® hip stems are similar to components previously cleared with the implaFit® hip stems (K210678). Both feature Equivalence: cementless femoral hip stems that are monoblock, tapered (12/14) and made from titanium alloy. The indications for the {6}------------------------------------------------ subject and predicate devices are identical, with the exception of the implaFit® hip stems also include hip stems for cemented use, as well as cementless; equivalence is only claimed for the cementless indications. There are some differences in stem material, geometry, and dimensions for the Actinia® hip stems as compared to the implaFit® hip stems predicate. These differences include stem coating, collarless design, cross-sectional geometry, stem length (shoulder to tip and lower shoulder to tip), neck length, and offset length. The Actinia® hip stems are substantially equivalent to the hip stems of the legally marketed predicate and reference device systems, the implaFit® him stems, DePuy Orthopaedics, Inc. Corail AMT Hip Prothesis and EcoFit® Hip System, with respect to design and intended use. - Performance Testing: All necessary testing has been performed for the "worst-case" components of the Actinia® hip stems to assure substantial equivalence to its predicate and reference devices and to demonstrate the subject devices perform as intended. All testing was performed on test units representative of or worstcase compared to the finished device. The following evaluations were conducted to characterize the devices: - Fatigue Testing (ISO 7206-4 and ISO 7206-6) ● - . Impingement Testing (ASTM F2582-14) - Taper Disassembly Testing (ASTM F2009) - Range of Motion (ROM) Evaluation (ISO 21535) - Coating Characterization (ASTM F1609, ASTM F1926, ● ASTM F2024, and ISO 13779) - Corrosion and Fretting Performance Rationale . The Actinia® hip stems subject to this submission possess the Conclusions: same intended use and similar technological characteristics as the predicate and reference device system components. All performance testing conducted for the Actinia® hip systems met the predetermined acceptance criteria or were otherwise considered acceptable. As such, the Actinia® hip stems components are substantially equivalent to the predicate devices for the intended use.
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%